Spontaneous adenocarcinoma mouse models for immunotherapy

Sandra J Gendler, Pinku Mukherjee

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Recent discoveries regarding the identification of tumor-associated antigens and antigen presentation have made successful immunotherapy strategies possible with little, if any, toxicity. Here, we describe transgenic mammary, pancreas, prostate, stomach and lung adenocarcinoma animal models that can be used to study various immunotherapeutic strategies. The challenge in developing a tumor vaccine is effective antigen presentation that elicits anti-tumor immune responses without precipitating autoimmunity. Clinical trials must be preceded by appropriate animal studies to demonstrate that the concepts can be translated into efficacious therapy for cancer. Although many xenograph or transplantable tumor models have been used, the most effective studies are in spontaneous tumor models. These models are clinically relevant, as tumors arise in an appropriate tissue background and in a host conditioned by the physiological events of neoplastic progression and tumorigenesis and in the context of a viable immune system.

Original languageEnglish (US)
Pages (from-to)471-475
Number of pages5
JournalTrends in Molecular Medicine
Volume7
Issue number10
DOIs
StatePublished - 2001

Fingerprint

Immunotherapy
Adenocarcinoma
Antigen Presentation
Neoplasms
Cancer Vaccines
Neoplasm Antigens
Autoimmunity
Prostate
Pancreas
Immune System
Stomach
Carcinogenesis
Breast
Animal Models
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Spontaneous adenocarcinoma mouse models for immunotherapy. / Gendler, Sandra J; Mukherjee, Pinku.

In: Trends in Molecular Medicine, Vol. 7, No. 10, 2001, p. 471-475.

Research output: Contribution to journalArticle

@article{86e48c1b22064c7382d662550f4cef33,
title = "Spontaneous adenocarcinoma mouse models for immunotherapy",
abstract = "Recent discoveries regarding the identification of tumor-associated antigens and antigen presentation have made successful immunotherapy strategies possible with little, if any, toxicity. Here, we describe transgenic mammary, pancreas, prostate, stomach and lung adenocarcinoma animal models that can be used to study various immunotherapeutic strategies. The challenge in developing a tumor vaccine is effective antigen presentation that elicits anti-tumor immune responses without precipitating autoimmunity. Clinical trials must be preceded by appropriate animal studies to demonstrate that the concepts can be translated into efficacious therapy for cancer. Although many xenograph or transplantable tumor models have been used, the most effective studies are in spontaneous tumor models. These models are clinically relevant, as tumors arise in an appropriate tissue background and in a host conditioned by the physiological events of neoplastic progression and tumorigenesis and in the context of a viable immune system.",
author = "Gendler, {Sandra J} and Pinku Mukherjee",
year = "2001",
doi = "10.1016/S1471-4914(01)02124-4",
language = "English (US)",
volume = "7",
pages = "471--475",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Spontaneous adenocarcinoma mouse models for immunotherapy

AU - Gendler, Sandra J

AU - Mukherjee, Pinku

PY - 2001

Y1 - 2001

N2 - Recent discoveries regarding the identification of tumor-associated antigens and antigen presentation have made successful immunotherapy strategies possible with little, if any, toxicity. Here, we describe transgenic mammary, pancreas, prostate, stomach and lung adenocarcinoma animal models that can be used to study various immunotherapeutic strategies. The challenge in developing a tumor vaccine is effective antigen presentation that elicits anti-tumor immune responses without precipitating autoimmunity. Clinical trials must be preceded by appropriate animal studies to demonstrate that the concepts can be translated into efficacious therapy for cancer. Although many xenograph or transplantable tumor models have been used, the most effective studies are in spontaneous tumor models. These models are clinically relevant, as tumors arise in an appropriate tissue background and in a host conditioned by the physiological events of neoplastic progression and tumorigenesis and in the context of a viable immune system.

AB - Recent discoveries regarding the identification of tumor-associated antigens and antigen presentation have made successful immunotherapy strategies possible with little, if any, toxicity. Here, we describe transgenic mammary, pancreas, prostate, stomach and lung adenocarcinoma animal models that can be used to study various immunotherapeutic strategies. The challenge in developing a tumor vaccine is effective antigen presentation that elicits anti-tumor immune responses without precipitating autoimmunity. Clinical trials must be preceded by appropriate animal studies to demonstrate that the concepts can be translated into efficacious therapy for cancer. Although many xenograph or transplantable tumor models have been used, the most effective studies are in spontaneous tumor models. These models are clinically relevant, as tumors arise in an appropriate tissue background and in a host conditioned by the physiological events of neoplastic progression and tumorigenesis and in the context of a viable immune system.

UR - http://www.scopus.com/inward/record.url?scp=0034787741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034787741&partnerID=8YFLogxK

U2 - 10.1016/S1471-4914(01)02124-4

DO - 10.1016/S1471-4914(01)02124-4

M3 - Article

C2 - 11597523

AN - SCOPUS:0034787741

VL - 7

SP - 471

EP - 475

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 10

ER -